Volume 47, Number 4, 648-651, DOI: 10.1007/s00125-004-1362-2

Published in partnership with the

Logo

European Association for the Study of Diabetes

Brain energy metabolism during hypoglycaemia in healthy and Type 1 diabetic subjects

M. G. Bischof, V. Mlynarik, A. Brehm, E. Bernroider, M. Krssak, E. Bauer, C. Madl, M. Bayerle-Eder, W. Waldhäusl and M. Roden

View Related Documents

Abstract

Aims/hypothesis  

This study aimed to examine brain energy metabolism during moderate insulin-induced hypoglycaemia in Type 1 diabetic patients and healthy volunteers.

Methods  

Type 1 diabetic patients (mean diabetes duration 13±2.5 years; HbA1c 6.8±0.3%) and matched controls were studied before, during (0–120 min) and after (120–240 min) hypoglycaemic (~3.0 mmol/l) hyperinsulinaemic (1.5 mU·kg–1·min–1) clamp tests. Brain energy metabolism was assessed by in vivo 31P nuclear magnetic resonance spectroscopy of the occipital lobe (3 Tesla, 10-cm surface coil).

Results  

During hypoglycaemia, the diabetic patients showed blunted endocrine counter-regulation. Throughout the study, the phosphocreatine:gamma-ATP ratios were lower in the diabetic patients (baseline: controls 3.08±0.29 vs diabetic patients 2.65±0.43, p<0.01; hypoglycaemia: 2.97±0.38 vs 2.60±0.35, p<0.05; recovery: 3.01±0.28 vs 2.60±0.35, p<0.01). Intracellular pH increased in both groups, being higher in diabetic patients (7.096±0.010 vs. 7.107±0.015, p<0.04), whereas intracellular magnesium concentrations decreased in both groups (controls: 377±33 vs 321±39; diabetic patients: 388±47 vs 336±68 µmol/l; p<0.05).

Conclusions/interpretation  

Despite a lower cerebral phosphocreatine:gamma-ATP ratio in Type 1 diabetic patients at baseline, this ratio does not change in control or diabetic patients during modest hypoglycaemia. However, both groups exhibit subtle changes in intracellular pH and intracellular magnesium concentrations.

Keywords  Cerebral metabolism - Hypoglycaemia counter-regulation - Insulin antagonists - Near-normoglycaemic insulin therapy - Phosphate compounds - Phosphorus-31 nuclear magnetic resonance spectroscopy - Type 1 diabetes mellitus

Fulltext Preview

Image of the first page of the fulltext document